, She also received consultant honorariums from Leo Pharma for the information booklet 'Anticoagulation pendant la grossesse, Dr Évelyne Rey received travel grants from Leo Pharma for the 4 th International Symposium on Women's Health Issues in Thrombosis and Hemostasis, 2009.
He is also a consultant for Sanofi, Stago, Leo Pharma, and LFB. He has received grants from Sanofi, Stago, Leo Pharma, LFB, and Baxter Healthcare Corporation. He has received payment for lectures including service on speakers bureaus forSanofi, Bayer, and Boehringer Ingelheim. Dr. Shannon Bates received an honoraria from Leo Pharma and Pfizer ,
, Dr Saskia Middeldorp: GSK supported the ALIFE trial with a grant, 2010.
, She has also received consulting fees and lecture honoraria from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Daiichi-Sankyo and research support from GSK, GSK currently supports the Highlow trial (has been taken over by Aspen in, 2014.
, He also received an honoraria from Pfizer, Ferring, Bayer-Jenapharm for various presentations
Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications, Blood, vol.123, pp.822-828, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-00935578
Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy, BJOG, vol.107, pp.785-791, 2000. ,
Assessment of uterine placental circulation in thrombophilic women, Semin Thromb Hemost, vol.29, pp.213-218, 2003. ,
Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta, J Matern Fetal Med, vol.7, pp.277-286, 1998. ,
Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells, Blood, vol.107, pp.3173-3180, 2006. ,
, Lancet, vol.376, pp.631-644, 2010.
, Pregnancy-related mortality in the United States, vol.88, pp.161-167, 1987.
Van Look PF: WHO analysis of causes of maternal death: a systematic review, Lancet, vol.367, pp.1066-1074, 2006. ,
, Report on confidential enquiries into maternal deaths in the United Kingdom 1994-1996. London: Her Majesty's Stationary Office, 1998.
, Maternal mortality in the United States, vol.76, pp.1055-1060, 1979.
Special Report on Maternal Mortality and Severe Morbidity in Canada. Enhanced Surveillance. The Path to Prevention, Canada: Minister of Public Works and Government Services, 2004. ,
Adult functional outcome of those born small for gestational age: twenty-six-year follow-up of the 1970 British Birth Cohort, JAMA, vol.283, pp.625-632, 2000. ,
Effects of intrauterine growth retardation in premature infants on early childhood growth, J Pediatr, vol.130, pp.95-102, 1997. ,
Growth and development of term children born with low birth weight: effects of genetic and environmental factors, J Pediatr, vol.133, pp.67-72, 1998. ,
Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia, Am J Obstet Gynecol, vol.195, pp.723-728, 2006. ,
Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis, Am J Obstet Gynecol, vol.165, pp.1408-1412, 1991. ,
Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas, Am J Obstet Gynecol, vol.186, pp.422-426, 2002. ,
Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data, Lancet, vol.369, pp.1791-1798, 2007. ,
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis, Obstet Gynecol, vol.116, pp.402-414, 2010. ,
Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT, J Thromb Haemost, vol.10, pp.64-72, 2012. ,
Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial, Thromb Haemost, vol.106, pp.1053-1061, 2011. ,
Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women, Hypertension, vol.45, pp.86-91, 2005. ,
Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial, J Thromb Haemost, vol.7, pp.58-64, 2009. ,
Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial, Thromb Haemost, vol.104, pp.771-779, 2010. ,
Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial, Blood, vol.119, pp.3269-3275, 2012. ,
Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin, Gynecol Obstet Invest, vol.49, pp.67-69, 2000. ,
Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy, Blood, vol.106, pp.401-407, 2005. ,
High rate of skin complications due to low-molecular-weight heparins in pregnant women, J Thromb Haemost, vol.1, pp.859-861, 2003. ,
Thrombophilia and placenta-mediated pregnancy complications: from the bench to bedside to policy, Thromb Res, vol.123, pp.96-100, 2008. ,
Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial, J Thromb Haemost, vol.5, pp.1600-1606, 2007. ,
The devil is in the details?or not? A primer on individual patient data meta-analysis, ACP Journal Club, vol.151, pp.1-3, 2009. ,
Individual patient data meta-analyses, Best Pract Res Clin Obstet Gynaecol, vol.19, pp.47-55, 2005. ,
A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis, J ClinEpidemiol, vol.55, pp.86-94, 2002. ,
An evidence-based practice guideline for the peer review of electronic search strategies, J Clin Epidemiol, vol.62, pp.944-952, 2009. ,
for the ETHIG Investigator Group: Low-molecular-weight heparin in recurrent pregnancy loss-Results of the ETHIG II study ,
, Thromb Res, vol.131, p.73, 2013.
Efficacy of three different antithrombotic regimens on pregnancy outcome in pregnant women affected by recurrent pregnancy loss, J Matern Fetal Neonatal Med, vol.25, pp.1191-1194, 2012. ,
Low molecular weight heaprin (LMWH) for treatment of recurrent miscarriage negatively tested for antiphospholipid antibodies: a randomized controlled trial ,
, Fertil Steril, vol.98, p.191, 2012.
Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial, Thromb Haemost, vol.105, pp.295-301, 2011. ,
SPIN: the Scottish Pregnancy Intervention Study: a multicentrerandomised controlled trial of low molecular weight heparin and low dose aspirin in women with recurrent miscarriage, Blood, vol.115, pp.4162-4167, 2010. ,
Aspirin plus heparin or aspirin alone in women with recurrent miscarriage, N Engl J Med, vol.362, pp.1586-1596, 2010. ,
Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial, J Rheumatol, vol.36, pp.279-287, 2009. ,
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients, J Thromb Haemost, vol.3, pp.692-694, 2005. ,
Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated, 2011. ,
Low-molecular-weight heparin for prevention of placenta-mediated pregnancy complications: protocol for a systematic review and individual patient data meta-analysis (AFFIRM), Systematic Reviews, vol.3, p.69, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01945886